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Tuberculosis (TB) is still a deadly disease in 2019. It 
ranks among the top 10 causes of death globally and 
is the most frequent cause of death from a single infec-
tious agent. TB remains a major public health problem 
worldwide, with the highest disease burden in low- 
and middle-income countries; according to the World 
Health Organization (WHO), an estimated 10 million 
people fell ill with tuberculosis in 2017, 1.5 million of 
whom died [1]. Children under 5 years of age are espe-
cially at risk of developing severe disease manifesta-
tions such as meningeal or disseminated disease and 
are therefore at higher risk of death and sequelae. In 
addition, young children with untreated latent TB infec-
tion (LTBI) or disease may experience reactivated TB 
later in life, which poses a major obstacle for elimina-
tion of the disease.
A total of 3% of global TB cases occur in the WHO 
European Region [1]. From a global perspective, the 
European Union/European Economic Area (EU/EEA)—
which comprises 31 of the 53 countries in the Region—
is making much progress, with decreasing numbers of 
people getting sick from TB or dying from the disease 
[2]. Despite this improvement, several problems remain 
that need to be considered. In the EU/EEA, the fre-
quency and burden of TB varies considerably between 
countries, with country-specific notification rates rang-
ing from 2.6 in Liechtenstein to 66.2 per 100,000 in 
Romania [2]. Within the EU/EEA, TB is largely a disease 
of the poor, affecting the most vulnerable and impov-
erished population groups. In Portugal, for example, 
unemployed individuals were shown to be at higher 
risk of developing TB [3]. In France, the TB notifica-
tion rate is 10 times higher in foreign-born individuals 
compared with the native population, and in homeless 
individuals this rate was 166 per 100,000 in 2015 [4]. 
Though the EU/EEA has a relatively low incidence of TB 
compared to the rest of the world, thousands of people 
still die from the disease every year, even though it can 
usually be cured by timely treatment with an adequate 
and complete drug regimen. The high number of mul-
tidrug-resistant (MDR) TB cases in some countries 
remains a constant threat for local populations and, 
because of travel and migration, also puts at risk those 
living in bordering countries and other parts of Europe. 
At 3.8%, the proportion of MDR TB in Germany in 2017 
was almost four times higher in foreign-born individu-
als compared to those born in Germany (1.0%); for 
those born in the newly independent states of the for-
mer Soviet Union, this proportion was almost 20 times 
higher (19.3%) [5].
The present issue of Eurosurveillance features two 
articles that discuss issues that the EU/EEA is facing 
regarding TB control. The incidence of TB in most EU/
EEA countries is decreasing and this is encouraging. 
However, one important question is whether the cur-
rent rate of decrease is enough to meet the targets that 
all WHO Member States committed to in 2015 to reduce 
cases of TB and deaths from the disease [6]. This point 
is discussed by Merk et al., who describe the trends of 
TB incidence and deaths reported in the EU/EEA during 
the last decade [7]. The authors show that despite a 
clear annual decline in cases and deaths, the trend is 
not enough to reach the set objectives. They also point 
out that some countries are progressing towards end-
ing TB faster than others, and underline the need to 
adapt prevention and control measures to a particular 
country’s situation. Despite substantial improvements 
in TB control in the EU/EEA, and the fact that the dis-
ease is progressively becoming rare in many countries, 
Merk et al. highlight that further progress in controlling 
and finally eliminating this severe disease will require 
a constant effort that is continually adapted to suit dis-
tinct geographical areas and the most affected popula-
tion groups.
Treatment outcome of TB patients and factors that may 
influence treatment success are further key points in TB 
control, and these are discussed in an article by Karo 
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et al. in this issue of Eurosurveillance [8]. Adequate 
treatment of a TB case cures the patient, rapidly limits 
the risk of transmission of Mycobacterium tuberculosis 
to close contacts in the family and community, and pre-
vents the development of resistance to anti-TB drugs. 
Therefore, assessing patients’ treatment outcome 
remains essential for evaluating national TB control 
programs; further, identifying factors associated with 
an unfavourable outcome may help to target control 
measures in groups that are most at need. In their anal-
ysis of factors influencing treatment outcome of TB in 
Europe, Karo et al. showed an almost nine times higher 
risk of unsuccessful treatment for patients with MDR 
TB (Odds ratio (OR): 8.7; 95% confidence interval (CI): 
5.09–14.97) [9]. The retrospective analysis in this issue 
used information on treatment outcome compiled by 
the European Centre for Disease Prevention and Control 
(ECDC) in the European Surveillance System (TESSy) 
database to investigate the association between iso-
niazid (INH) mono-resistance and TB treatment suc-
cess. The results show that treatment success did not 
meet the objectives set by WHO in 2014 [6] and that 
treatment success for INH mono-resistant TB was sig-
nificantly lower compared with fully drug-susceptible 
TB. The authors compare their results to those already 
published and conclude that increased efforts should 
be made towards timely detection and management of 
INH mono-resistant TB, which is frequently underesti-
mated. Timely drug sensitivity testing of all cases and 
provision of treatment regimens adapted to the strain 
profile are essential components of TB control that con-
tribute to maintaining a low prevalence of INH mono-
resistance observed in the EU/EEA [10]. The timely 
identification and management of patients infected 
with a strain resistant to INH, one of the most impor-
tant first-line drugs for the treatment of TB, should also 
prevent further development of MDR TB, which remains 
low overall in most countries of the EU/EEA [2].
It is clear that ending the TB epidemic poses tremen-
dous challenges and requires a concerted international 
effort. Following the 1993 WHO alert declaring that TB 
was a global emergency [11], several initiatives (e.g. 
Stop TB Partnership), sources of funding (e.g. The 
Global Fund) and political declarations have shown that 
the international community is committed to the global 
goal of ending the TB epidemic. In November 2017, 
the first WHO global ministerial conference on ending 
TB was held in the Russian Federation and brought 
together 75 ministers of health, resulting in the Moscow 
Declaration to End TB [12]. The conference recognised 
that today TB is the most deadly infectious disease in 
the world, with considerable economic and social con-
sequences. On 26 September 2018, the United Nations 
first high-level meeting on TB in New York highlighted 
the need for immediate action to accelerate progress 
towards the goal of ending the TB epidemic by 2030. In 
the political declaration, national leaders committed to 
taking specific actions against TB [13].
The elimination of TB in the EU/EEA, where a grow-
ing number of countries are progressively entering the 
low-incidence category, poses several challenges, as 
illustrated by the two articles presented in this issue 
of Eurosurveillance. The elimination of TB in this region 
will require additional efforts and specific actions 
that have been adapted to local epidemiology [14]. 
Treatment outcome needs to improve, particularly in 
drug-resistant TB cases, including cases with MDR TB, 
which is associated with the highest rates of unsuccess-
ful treatment [9]; in order to achieve this, a wider use 
of rapid molecular testing and the adaptation of treat-
ment regimens are necessary. Continual involvement of 
TB professionals and close collaboration between clini-
cians, microbiologists and epidemiologists working in 
the field are also needed. Immediate contact investiga-
tions performed around each newly detected case will 
help to prevent the occurrence of new cases. The use 
of genotyping methods to identify related cases and to 
understand chains of transmission should further help 
to get closer to a zero transmission goal.
In low-incidence countries, the majority of TB cases are 
generated through reactivation of latent TB infections 
(LTBI) acquired abroad [14]. As global migration has 
increased considerably in recent decades [15,16] and 
a significant proportion of TB cases in most EU/EEA 
countries are born in countries with a high incidence 
of TB [2], early detection and access to health services 
and care in this specific group should be placed as one 
of the top priorities of TB control. In addition, individu-
als with LTBI represent an important reservoir, as they 
may later progress to TB disease, therefore contribut-
ing to future TB burden. In the WHO European Region 
the prevalence of LTBI has been estimated at 13.7%; 
this prevalence is 0.3% for recent infections [17], which 
have the highest risk of progressing towards TB. An 
important challenge for European control programs 
is therefore to establish a programmatic approach to 
LTBI management that takes into account the TB epi-
demiology in various vulnerable groups, as well as the 
health system structure, resource allocation and politi-
cal commitment [18]. This underlines that there is not 
one single issue to address, but rather that a strate-
gic, comprehensive approach needs to be developed in 
order to meet the challenge of TB elimination.
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